Investment in R&D Activities by Pharmaceutical and Biotechnology Companies and Rising Number of diseases are expected to Drive the Global Mycoplasma Testing in Clinical Market in the forecast period of 2019 -2026

Global Mycoplasma Testing in Clinical Market is projected to register a healthy CAGR of 12.6% in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Access Full Report at https://databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market

Drivers: Global Mycoplasma Testing in Clinical Market

  • Investment in R&D activities by pharmaceutical and biotechnology companies
  • Rising number of diseases

Restraints:

  • High cost of instruments
  • Stringent government regulations

 Opportunity:

  • Availability of number of techniques for detection of mycoplasma

Challenge:

  • Lack of skilled professionals

 Market Trends:

Global mycoplasma testing in clinical market is segmented into four notable segments which are products, technique, disease area and end user.

  • On the basis of products, the market is segmented into kits & reagents, Instruments and services.  The kits and reagents segment is dominating the global mycoplasma testing in clinical market.
  • On the basis of technique, the market is segmented into polymerase chain reaction, ELISA, DNA staining/ indirect assay, enzymatic methods, microbial culture techniques /direct assay and others
  • On the basis of disease area, the market is segmented into, urogenital, respiratory, cardiovascular, musculoskeletal, gastrointestinal and others
  • On the basis of end user, the market is segmented into hospitals, diagnostic laboratories and others

Major Players: Global Mycoplasma Testing in Clinical Market

Some of the major players operating in this market are Sartorius AG, MERCK KGAA, ELITechGROUP, AB ANALITICA srl, GOLD STANDARD DIAGNOSTICS, OSANG Healthcare, BioFire Diagnostics, PromoCell GmbH, Lonza, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Liofilchem Srl, ZEAKON Diagnostics, OPERON, Bio-Rad Laboratories, Inc., Sacace Biotechnologies Srl and Seegene Inc., among others